Literature DB >> 2476804

Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling.

R C Baxter1, J L Martin.   

Abstract

To determine the structure of the high molecular weight, growth hormone-dependent complex between the insulin-like growth factors (IGF-I and IGF-II) and their binding proteins in human serum, we have reconstituted the complex from its purified component proteins and analyzed it by gel electrophoresis and autoradiography after covalent cross-linking. The proteins tested in reconstitution mixtures were an acid-labile Mr 84,000-86,000 glycoprotein doublet (alpha subunit), an acid-stable Mr 47,000-53,000 glycoprotein doublet with IGF-binding activity (BP-53 or beta subunit), and IGF-I or IGF-II (gamma subunit). In incubations containing any one of the three subunits 125I-labeled and the other two unlabeled, identical 125I-labeled alpha-beta-gamma complexes of Mr 140,000 were formed. Minor bands of Mr 120,000 and 90,000 were also seen, thought to represent a partially deglycosylated form of the alpha-beta-gamma complex, and an alpha-gamma complex arising as a cross-linking artifact. When serum samples from subjects of various growth hormone status were affinity-labeled with IGF-II tracer, a growth hormone-dependent Mr 140,000 band was seen, corresponding to the reconstituted alpha-beta-gamma complex. Other growth hormone-dependent labeled bands, of Mr 90,000 (corresponding to alpha-gamma), Mr 55,000-60,000 (corresponding to labeled beta-subunit doublet), and smaller bands of Mr 38,000, 28,000, and 23,000-25,000 (corresponding to labeled beta-subunit degradation products), were also seen in the affinity-labeled serum samples and in the complex reconstituted from pure proteins. All were immunoprecipitable with an anti-BP-53 antiserum. We conclude that the growth hormone-dependent Mr 140,000 IGF-binding protein complex in human serum has three components: the alpha (acid-labile) subunit, the beta (binding) subunit, and the gamma (growth factor) subunit.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476804      PMCID: PMC297957          DOI: 10.1073/pnas.86.18.6898

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Somatomedin-C/insulin-like growth factor I-binding proteins in human amniotic fluid and in fetal and postnatal blood: evidence of immunological homology.

Authors:  A J D'Ercole; S L Drop; D J Kortleve
Journal:  J Clin Endocrinol Metab       Date:  1985-10       Impact factor: 5.958

2.  Two immunoreactive binding proteins for insulin-like growth factors in human amniotic fluid: relationship to fetal maturity.

Authors:  R C Baxter; J L Martin; M H Wood
Journal:  J Clin Endocrinol Metab       Date:  1987-09       Impact factor: 5.958

3.  High molecular weight forms of insulin-like growth factor II and its binding protein identified by protein immunoblotting.

Authors:  P D Lee; D R Powell; C H Li; H Bohn; F Liu; R L Hintz
Journal:  Biochem Biophys Res Commun       Date:  1988-05-16       Impact factor: 3.575

4.  Growth hormone-dependent insulin-like growth factor (IGF) binding protein from human plasma differs from other human IGF binding proteins.

Authors:  R C Baxter; J L Martin; M I Tyler; M E Howden
Journal:  Biochem Biophys Res Commun       Date:  1986-09-30       Impact factor: 3.575

5.  Covalent cross-linking of insulin-like growth factor-1 to a specific inhibitor from human serum.

Authors:  G T Ooi; A C Herington
Journal:  Biochem Biophys Res Commun       Date:  1986-05-29       Impact factor: 3.575

6.  Insulin-like growth factor-binding protein from human plasma. Purification and characterization.

Authors:  J L Martin; R C Baxter
Journal:  J Biol Chem       Date:  1986-07-05       Impact factor: 5.157

7.  Heterogeneity of insulin-like growth factor binding proteins and relationships between structure and affinity. 1. Circulating forms in man.

Authors:  S Hardouin; P Hossenlopp; B Segovia; D Seurin; G Portolan; C Lassarre; M Binoux
Journal:  Eur J Biochem       Date:  1987-12-30

8.  Affinity-labeled plasma somatomedin-C/insulinlike growth factor I binding proteins. Evidence of growth hormone dependence and subunit structure.

Authors:  J R Wilkins; A J D'Ercole
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

9.  Measurement of insulin-like growth factor-II by radioreceptor assay using ovine placental membranes.

Authors:  R C Baxter; J S de Mellow
Journal:  Clin Endocrinol (Oxf)       Date:  1986-03       Impact factor: 3.478

10.  Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma.

Authors:  R C Baxter; J L Martin
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

View more
  41 in total

Review 1.  Minor head injury.

Authors:  T F Beattie
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

2.  Reduced levels of growth hormone, insulin-like growth factor-I and binding protein-3 in patients with shunted hydrocephalus.

Authors:  T Löppönen; A L Saukkonen; W Serlo; P Tapanainen; A Ruokonen; M Knip
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

Review 3.  The insulin-like growth factor family of ligands, receptors, and binding proteins.

Authors:  R F Krywicki; D Yee
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions: evidence for a role for insulin-like growth factor I.

Authors:  R Hirschberg
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

5.  Failure of IGF-I and IGFBP-3 to diagnose growth hormone insufficiency.

Authors:  H Mitchell; M T Dattani; V Nanduri; P C Hindmarsh; M A Preece; C G Brook
Journal:  Arch Dis Child       Date:  1999-05       Impact factor: 3.791

6.  Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system.

Authors:  I Ueki; G T Ooi; M L Tremblay; K R Hurst; L A Bach; Y R Boisclair
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

7.  Serum "big insulin-like growth factor II" from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing.

Authors:  W H Daughaday; B Trivedi; R C Baxter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

8.  Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism.

Authors:  Shoshana Yakar; Clifford J Rosen; Mary L Bouxsein; Hui Sun; Wilson Mejia; Yuki Kawashima; Yingjie Wu; Kelly Emerton; Valerie Williams; Karl Jepsen; Mitchell B Schaffler; Robert J Majeska; Oksana Gavrilova; Mariana Gutierrez; David Hwang; Patricia Pennisi; Jan Frystyk; Yves Boisclair; John Pintar; Héctor Jasper; Horacio Domene; Pinchas Cohen; David Clemmons; Derek LeRoith
Journal:  FASEB J       Date:  2008-10-24       Impact factor: 5.191

9.  Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor.

Authors:  Yingjie Wu; Hui Sun; Jelena Basta-Pljakic; Luis Cardoso; Oran D Kennedy; Hector Jasper; Horacio Domené; Liliana Karabatas; Clara Guida; Mitchell B Schaffler; Clifford J Rosen; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

Review 10.  Pharmacomimetics of exercise: novel approaches for hippocampally-targeted neuroprotective agents.

Authors:  A M Stranahan; Y Zhou; B Martin; S Maudsley
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.